Combinational Treatment of Imatinib and Allicin Synergistically Inhibits the Growth of BCR-ABL-Positive Leukemia and the Emergence of Drug-Resistant Cells

被引：0
|
作者：
Lim, Jamie
Kim, Jung-Hyun
Ahn, Eun-Young Erin
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4992
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Tanaka, Yuko
    Katagiri, Seiichiro
    Kitahara, Toshihiko
    Ohyashiki, Kazuma
    BLOOD, 2013, 122 (17) : 3086 - 3088
  • [32] Reversal of Imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na+/H+ exchanger
    Jin, Weina
    Li, Qinghua
    Lin, Yani
    Lu, Ying
    Li, Huawen
    Wang, Lihong
    Hu, Ronghua
    Ma, Li
    Wang, Jianxiang
    Pang, Tianxiang
    CANCER LETTERS, 2011, 308 (01) : 81 - 90
  • [33] Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo
    Wahiduzzaman, Md
    Ota, Akinobu
    Karnan, Sivasundaram
    Hanamura, Ichiro
    Mizuno, Shohei
    Kanasugi, Jo
    Rahman, Md Lutfur
    Hyodo, Toshinori
    Konishi, Hiroyuki
    Tsuzuki, Shinobu
    Takami, Akiyoshi
    Hosokawa, Yoshitaka
    CANCER LETTERS, 2018, 433 : 117 - 130
  • [34] Case report: BCR-ABL-positive acute lymphoblastic leukemia with bone destruction: a treatment dilemma
    Shi, Lijun
    Ma, Zhongrui
    Li, Wei
    Xia, Yu
    Wei, Jiang
    Pan, Yaning
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [35] The anti-apoptotic role of the unfolded protein response in Bcr-Abl-positive leukemia cells
    Tanimura, Atsuko
    Yujiri, Toshiaki
    Tanaka, Yoshinori
    Hatanaka, Masayuki
    Mitani, Noriyuki
    Nakamura, Yukinori
    Mori, Kazutoshi
    Tanizawa, Yukio
    LEUKEMIA RESEARCH, 2009, 33 (07) : 924 - 928
  • [36] Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib
    Ritchie, David S.
    McBean, Michelle
    Westerman, David A.
    Kovalenko, Sergey
    Seymour, John F.
    Dobrovic, Alexander
    BLOOD, 2008, 111 (05) : 2896 - 2898
  • [37] Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia
    Fujisawa, Shin
    Mizuta, Shuichi
    Akiyama, Hideki
    Ueda, Yasunori
    Aoyama, Yasutaka
    Hatta, Yoshihiro
    Kakihana, Kazuhiko
    Dobashi, Nobuaki
    Sugiura, Isamu
    Onishi, Yasushi
    Maeda, Tomoya
    Imai, Kiyotoshi
    Ohtake, Shigeki
    Miyazaki, Yasushi
    Ohnishi, Kazunori
    Matsuo, Keitaro
    Naoe, Tomoki
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (04) : 367 - 374
  • [38] Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells
    Chen, Chun
    Zhuang, Yingting
    Chen, Xianling
    Chen, Xiaole
    Li, Ding
    Fan, Yingjuan
    Xu, Jianhua
    Chen, Yuanzhong
    Wu, Lixian
    ONCOTARGET, 2017, 8 (06) : 10025 - 10036
  • [39] Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
    Y Kawaguchi
    I Jinnai
    K Nagai
    F Yagasaki
    Y Yakata
    T Matsuo
    K Kuriyama
    M Tomonaga
    Leukemia, 2001, 15 : 590 - 594
  • [40] Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
    Kawaguchi, Y
    Jinnai, I
    Nagai, K
    Yagasaki, F
    Yakata, Y
    Matsuo, T
    Kuriyama, K
    Tomonaga, M
    LEUKEMIA, 2001, 15 (04) : 590 - 594
12345